Buchumschlag

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years

Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged <65 years. To understand age-related trends in utilisation and outcome of AHCT, we analysed 53 675 MM patients who underwent a first AHCT in 31 European countries between 1991 and 201...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Auner, Holger (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2015
In: Bone marrow transplantation
Year: 2014, Jahrgang: 50, Heft: 2, Pages: 209-215
ISSN:1476-5365
DOI:10.1038/bmt.2014.255
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1038/bmt.2014.255
Verlag, Volltext: http://www.redi-bw.de/db/ebsco.php/search.ebscohost.com/login.aspx%3fdirect%3dtrue%26db%3da9h%26AN%3d100775159%26lang%3dde%26site%3deds-live
Volltext
Verfasserangaben:H.W. Auner, R. Szydlo, J. Hoek, H. Goldschmidt, A.M. Stoppa, G.J. Morgan, P. Moreau, M. Attal, G. Marit, N. Russell, M. Brune, G. Cook, P. Sonneveld, S. Schönland, L. Garderet, and N. Kröger
Beschreibung
Zusammenfassung:Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged <65 years. To understand age-related trends in utilisation and outcome of AHCT, we analysed 53 675 MM patients who underwent a first AHCT in 31 European countries between 1991 and 2010. The number of patients undergoing AHCT increased for all age groups (<40, 40-49, 50-59, 60-64, 65-69 and ⩾70 years) throughout the observation period. The highest increase was observed for patients aged ⩾65 years, who accounted for 3% of AHCTs in 1991-1995 and for 18.8% of AHCTs in 2006-2010. Risk factors associated with survival over the entire observation period (P<0.001) were calendar period, remission status at AHCT, gender, disease duration before AHCT and age. Survival improved considerably more in older than in younger patients in recent years. In 2006-2010, median 2- and 5-year post-transplant survival ranged from 85.9 and 61.5% in patients <40 years to 80.2 and 49.7% in those ⩾70 years. All-cause day-100 mortality decreased throughout the observation period to ⩽2.4% for all age groups in 2006-2010. The results of this study demonstrate increased utilisation and safety of AHCT with improved post-transplant survival particularly in elderly MM patients in recent years in Europe.
Beschreibung:Published online: 10 November 2014
Gesehen am 22.06.2017
Beschreibung:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2014.255

Ähnliche Einträge